Evidence map›Paper›PMID 26659823›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2016

All-trans retinoic acid potentiates cisplatin-induced kidney injury in rats: impact of retinoic acid signaling pathway.

Abdelrahman M Elsayed, Tamer M Abdelghany, El-Sayed Akool, Abdel-Aziz H Abdel-Aziz, Mohamed S Abdel-Bakky

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. The yin and yang of retinoic acid signaling in kidney diseases.The Journal of clinical investigation · 2020
    Article
  4. Article
  5. All-American journal of physiology. Renal physiology · 2017
    Article
  6. [Research advances in the protective effect of all-trans retinoic acid against podocyte injury].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Abdelrahman M ElsayedFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Tamer M AbdelghanyFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt. tamer_ibrahim2@yahoo.com.
El-Sayed AkoolFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Abdel-Aziz H Abdel-AzizFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Mohamed S Abdel-BakkyFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Al-Azhar University · EGAl Jouf University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin (cis-diammine dichloroplatinum (II), CDDP) is a widely used drug for treatment of various types of cancers. However, CDDP-induced nephrotoxicity remains the main dose-limiting side effect. Retinoids are a group of vitamin A-related compounds that exert their effects through retinoid receptors activation. In this study, we investigated the effect of CDDP treatment on retinoic acid receptor-α (RAR-α) and retinoid X receptor-α (RXR-α) expression. In addition, we investigated the possible modulatory effects of RAR agonist, all-trans retinoic acid (ATRA), on CDDP-induced nephrotoxicity. Rats were treated with saline, DMSO, CDDP, ATRA, or CDDP/ATRA. Twenty-four hours after the last ATRA injection, rats were killed; blood samples were collected; kidneys were dissected; and biochemical, immunohistochemical, and histological examinations were performed. Our results revealed that CDDP treatment significantly increased serum levels of creatinine and urea, with concomitant decrease in serum albumin. Moreover, reduced glutathione (GSH) content as well as superoxide dismutase (SOD) and catalase (CAT) activities were significantly reduced with concurrent increase in kidney malondialdehyde (MDA) content following CDDP treatment. Furthermore, CDDP markedly upregulated tubular RAR-α, RXR-α, fibrin, and inducible nitric oxide synthase (iNOS) protein expression. Although administration of ATRA to control rats did not produce marked alterations in kidney function parameters, administration of ATRA to CDDP-treated rats significantly exacerbated CDDP-induced nephrotoxicity. In addition, CDDP/ATRA co-treatment significantly increased RAR-α, RXR-α, fibrin, and iNOS protein expression compared to CDDP alone. In conclusion, we report, for the first time, the crucial role of retinoid receptors in CDDP-induced nephrotoxicity. Moreover, our findings indicate that co-administration of ATRA with CDDP, although beneficial on the therapeutic effects, their deleterious effects on the kidney may limit their clinical use.

Indexed as

AnimalsAntineoplastic AgentsCisplatinDrug SynergismFibrinKidneyKidney DiseasesMaleNitric Oxide Synthase Type IIOxidative StressRatsRats, Sprague-DawleyReceptors, Retinoic AcidRetinoic Acid Receptor alphaRetinoid X ReceptorsSignal TransductionAntineoplastic AgentsCisplatinFibrinNitric Oxide Synthase Type IINos2 protein, ratReceptors, Retinoic AcidRetinoic Acid Receptor alphaRetinoid X ReceptorsTretinoinAll-trans retinoic acidCisplatin nephrotoxicityFibrinInducible nitric oxide synthaseRetinoic acid receptor alphaRetinoid X receptor alpha

Identifiers

PMID26659823
OpenAlexW2293345240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.